Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eltrombopag for Thrombocytopenia in Relapsed Multiple Myeloma
NCT01484314Phase 2Terminated
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Apr 2012
- Primary completion
- Sep 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of eltrombopag in Thrombocytopenia, sponsored by Dana-Farber Cancer Institute. Primary endpoints: Maintenance of Platelet Count at 2 years and Safety and Tolerability at 2 years. Started Apr 2012; status: terminated.
02
Drugs
eltrombopag
03
Conditions
Thrombocytopenia
Beyond the preview
Go deeper on NCT01484314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01484314.